主页 > 医学讨论 >
【技术产业】生物技术产业新闻
* Report: More biotech firms to team up with CROs
Small ***aceutical and biotech firms are likely to seek help from contract research organizations to develop drugs in Phase I trials, according to a report from Turner Investment Partners. Biotech companies generated 30% of annual worldwide revenue for CROs, which are expected to be part of up to 50% of projects involving medicines in pre-clinical and clinical development, the report said. In-PharmaTechnologist.com (7/28)
Are you prepared to meet the CA Prescription Drug Pedigree Regulations?
IBM's RFID for Pharmaceutical Track and Trace may be right for your needs,even beyond compliance.
Click here to learn more.
Health Care & Policy
* Researchers find clue to rare degenerative disease
Australian researchers have identified the processes responsible for the accumulation of toxic iron in the cells of people with Friedreich's ataxia, a rare degenerative disease that can impair coordination and walking ability. The finding could lead to the development of novel drugs aimed at eliminating toxic iron, one of the scientists said. The Sydney Morning Herald (7/28)
* Study shows potential of microRNAs as cancer biomarkers
U.S. scientists were able to distinguish prostate cancer patients from healthy individuals after examining microRNAs in their blood. Researchers found that microRNAs originate from cancer cells and circulate in the blood, making them "a worthwhile class of molecules to study for the purpose of early cancer detection," a study author said. Yahoo!/HealthDay News (7/28)
Company & Financial News
* Web millionaire's firm promotes patient-funded research
CollabRx, a company founded by Internet millionaire and cancer survivor Jay M. Tenenbaum, works to speed up the discovery of drugs for rare diseases by tapping into patient-supported research. The firm aims to broaden the approach with integrated projects called virtual biotechs and a Web network that allows data sharing among researchers. Some experts questioned CollabRx's strategy, citing the competitive culture of academic scientific research that could make collaboration difficult. The Wall Street Journal (free content) (7/29)
* Biovail founder pulls board challenge, plans new company
Biovail founder Eugene Melnyk gave up his challenge to the company's election for the board of directors, saying he will instead form a private drug firm. Melnyk pushed for the development of hard-to-formulate generic drugs to revive lackluster sales, but the Canadian drugmaker's management wanted to focus on medicines for diseases of the central nervous system, including multiple sclerosis. Melnyk said his decision is in "everyone's best interest -- particularly the shareholders of Biovail." Bloomberg (7/28)
* Lilly to unveil dual approach in Alzheimer's treatment
Eli Lilly and Co. is set to present its two-pronged approach to treating Alzheimer's disease at an international conference in Chicago this week. The drugs -- an oral medicine in Phase III trials and an intravenous treatment in midstage testing -- work by decreasing amyloid beta protein that accumulates in the brain and destroys brain cells. The Indianapolis Star (7/29)
* Vanda faces setback in FDA approval of schizophrenia drug
The FDA sent a not-approvable letter to Vanda Pharmaceuticals for iloperidone and asked for more studies to compare the efficacy of the schizophrenia-drug candidate with rivals such as Johnson & Johnson's Risperdal and Eli Lilly and Co.'s Zyprexa. Vanda plans to discuss the decision with the agency, which also requested more safety data on the long-term effects of the drug when taken in 20 mg to 24 mg doses. American City Business Journals/Baltimore (7/28) , Bloomberg (7/28)
* FDA grants orphan-drug status for skin-disease treatment
The FDA granted orphan-drug designation to Clinuvel Pharmaceuticals' afamelanotide as a treatment for erythropoietic porphyrias, a rare genetic disorder common in fair-skinned people. The orphan-drug status is a first for Clinuvel, which is developing afamelanotide to treat patients with ultraviolet-related skin diseases. The Sydney Morning Herald/Australian Associated Press (7/29)
Global Developments
* Dr. Reddy's to set up joint venture for follow-on biologics
Dr. Reddy's Laboratories is in talks with an undisclosed biotech company over plans to establish a joint venture that will focus on the development of follow-on biologics. The collaboration would concentrate initially on the development of off-patent cancer medicines and eight potential drugs, Dr. Reddy's CEO said. Business Standard (India) (7/29)
Food & Agriculture
* Tight security needed for biotech crop trials, scientists say
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-07 05:14
医学,生命科学网